Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer

Table 1 Patient baseline characteristics n (%)

Characteristics	Value
n	40
Age (yr), median (range)	55.50 (26-76)
Gender
Male	22 (55.0)
Female	18 (45.0)
Primary tumor location
Colon cancer	10 (25.0)
Rectal cancer	30 (75.0)
ECOG
0-1	31 (77.5)
≥ 2	9 (22.5)
Metastatic sites
Liver only	6 (15.0)
Lung only	4 (10.0)
Liver and lung only	8 (20.0)
2 sites, including liver or lung	6 (15.0)
2 sites, excluding liver and lung	2 (5.0)
≥ 3 sites	9 (22.5)
1 site, excluding liver and lung	5 (12.5)
Number of metastatic sites
1 site	15 (37.5)
≥ 2 sites	25 (62.5)
Histologic type
Well	9 (22.5)
Moderate	9 (22.5)
Poor	1 (2.5)
Unknown	21 (52.5)
Previous chemotherapy
Fluoropyrimidine + oxaliplatin	31
Fluoropyrimidine + irinotecan	25
Capecitabine combined	15
Fluoropyrimidine combined	6
Line number of bevacizumab
2nd line	17 (42.5)
3rd line	13 (32.5)
4th or later-line	10 (25.0)
Chemotherapy associated with bevacizumab
Oxaliplatin-combined	12 (30.0)
Irinotecan- combined	19 (47.5)
5-fluorouracil-combined	8 (20.0)
Bevacizumab alone	1 (2.5)

ECOG: Performance status score.